DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease
Latest Information Update: 10 Feb 2022
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin
- Indications Cardiovascular disorders; Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Therapeutic Use
- Acronyms DUAL-PAD
Most Recent Events
- 13 Jan 2022 Status changed from recruiting to completed.
- 27 Jun 2021 Planned number of patients changed from 330 to 159.
- 02 Nov 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2022.